Program
ibrutinib
Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 364 open or running | phase 4since Jun 14, 2017 | May 14, 2012 | Dec 31, 2026phase 3 · NCT01804686 |
| AbbVie | 341 open or running | phase 4since Jun 5, 2017 | Feb 20, 2009 | May 10, 2027phase 4 · NCT03229200 |
| Novartis | 21 open or running | phase 2since May 21, 2019 | Mar 13, 2019 | Jun 30, 2027phase 2 · NCT03960840 |
| BeOne Medicines | 10 open or running | phase 3since Feb 7, 2017 | Feb 7, 2017 | none ahead |
| Oncternal Therapeutics | 10 open or running | phase 3since Jun 9, 2022 | Jun 9, 2022 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Oct 9, 2012.
- Mar 6, 20182 phase 3 studiesJohnson & Johnson · NCT03462719, NCT03474679
- Dec 12, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeAbbVie · NCT03790332 · 59 enrolled · United States, Australia, Austria and more
- Mar 12, 2019Phase 2 study in LeukemiaAbbVie · NCT03873493 · 14 enrolled · United States, Australia, Austria and more
- Mar 13, 2019Novartis's first study: phase 1 study in Lymphoma, Large B-Cell, DiffuseNew to NovartisNovartis · NCT03876028 · 10 enrolled · United States
- May 21, 2019Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNovartis · NCT03960840 · 218 enrolled · United States, Australia, Austria and more
- Jul 31, 2019Phase 4 study in Waldenstrom MacroglobulinemiaJohnson & Johnson · NCT04042376 · 17 enrolled · China
- Aug 19, 2019Phase 2 study in Waldenstrom MacroglobulinemiaJohnson & Johnson · NCT04062448 · 16 enrolled · Japan
- May 4, 2020Phase 2 study in COVID-19AbbVie · NCT04375397 · 46 enrolled · United States
- Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellAbbVie · NCT04477486 · 13 enrolled · Japan
- Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT05105841 · 20 enrolled · Japan
- Jun 9, 2022Oncternal Therapeutics's first study: phase 3 study in Lymphoma, Mantle-CellNew to Oncternal TherapeuticsOncternal Therapeutics · NCT05431179
- Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellJohnson & Johnson · NCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
- Jul 19, 2023Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT05963074 · 333 enrolled · United States, Canada, Czechia and more
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteJohnson & Johnson · NCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT01804686
- May 10, 2027Primary completion: phase 4 study in Lymphoma, B-CellAbbVie · NCT03229200
- Jun 30, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNovartis · NCT03960840
- Dec 15, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT05963074
TargetBeta
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
The newest 60 of 74 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Johnson & Johnson | Jan 19, 2028 | 120 |
| NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Czechia and more | 2 | Active, not recruiting | Johnson & Johnson | Dec 15, 2027 | 333 |
| NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more | 2 | Completed | Johnson & Johnson | Dec 6, 2023 | 36 |
| NCT05431179Lymphoma, Mantle-Cell | 3 | Withdrawn | Oncternal Therapeutics | Nov 2026 | 0 |
| NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | AbbVie | Oct 9, 2025 | 20 |
| NCT04477486Lymphoma, Mantle-Cell · Japan | 2 | Completed | AbbVie | Feb 9, 2022 | 13 |
| NCT04375397COVID-19 · United States | 2 | Completed | AbbVie | May 10, 2021 | 46 |
| NCT04062448Waldenstrom Macroglobulinemia · Japan | 2 | Completed | Johnson & Johnson | Aug 24, 2021 | 16 |
| NCT04042376Waldenstrom Macroglobulinemia · China | 4 | Completed | Johnson & Johnson | Mar 19, 2024 | 17 |
| NCT03960840Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 2 | Active, not recruiting | Novartis | Jun 30, 2027 | 218 |
| NCT03876028Lymphoma, Large B-Cell, Diffuse · United States | 1 | Terminated | Novartis | Nov 1, 2021 | 10 |
| NCT03873493Leukemia · United States, Australia, Austria and more | 2 | Completed | AbbVie | Nov 4, 2021 | 14 |
| NCT03790332Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more | 2 | Completed | AbbVie | Oct 9, 2025 | 59 |
| NCT03474679Graft vs Host Disease · Japan | 3 | Completed | Johnson & Johnson | Nov 29, 2021 | 19 |
| NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more | 3 | Active, not recruiting | Johnson & Johnson | Feb 26, 2021 | 211 |
| NCT03301207Leukemia, Lymphocytic, Chronic, B-Cell · Poland, Spain | 1 | Completed | Johnson & Johnson | Jul 17, 2018 | 25 |
| NCT03190330Leukemia, Lymphocytic, Chronic, B-Cell · India | 4 | Completed | Johnson & Johnson | May 3, 2023 | 75 |
| NCT03229200Lymphoma, B-Cell · United States, Australia, Canada and more | 4 | Active, not recruiting | AbbVie | May 10, 2027 | 297 |
| NCT03053440Waldenstrom Macroglobulinemia · United States, Australia, Czechia and more | 3 | Completed | BeOne Medicines | Jun 21, 2022 | 201 |
| NCT02947347Lymphoma, Follicular · United States, Australia, Austria and more | 3 | Completed | AbbVie | Feb 21, 2024 | 445 |
| NCT02959944Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more | 3 | Completed | AbbVie | Mar 27, 2020 | 193 |
| NCT02910583Leukemia · United States, Australia, Italy and more | 2 | Completed | AbbVie | Nov 12, 2020 | 323 |
| NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more | 2 | Completed | AbbVie | Oct 26, 2018 | 74 |
| NCT02877225Healthy · United States | 1 | Completed | Johnson & Johnson | Nov 11, 2016 | 103 |
| NCT02841150Healthy · United States | 1 | Completed | Johnson & Johnson | Aug 2016 | 102 |
| NCT02703272Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more | 3 | Terminated | Johnson & Johnson | Jun 11, 2021 | 72 |
| NCT02638116Healthy · Belgium | 1 | Completed | Johnson & Johnson | Mar 2016 | 20 |
| NCT02599324Carcinoma, Renal Cell · United States, Korea, Republic of, Spain and more | 2 | Completed | AbbVie | Aug 20, 2021 | 263 |
| NCT02548962Multiple Myeloma · United States, Australia, Czechia and more | 2 | Terminated | AbbVie | Jun 13, 2018 | 11 |
| NCT02556892Leukemia, Lymphoid · Japan | 1 | Completed | Johnson & Johnson | Aug 20, 2018 | 8 |
| NCT02436668Metastatic Pancreatic Adenocarcinoma · United States, Belgium, France and more | 3 | Completed | AbbVie | Oct 2018 | 430 |
| NCT02390609Healthy · Belgium | 1 | Completed | Johnson & Johnson | Nov 2015 | 40 |
| NCT02381080Leukemia, Lymphocytic, Chronic, B-Cell · Canada, Russian Federation, Spain | 1 | Completed | Johnson & Johnson | Jun 24, 2016 | 26 |
| NCT02351037Leukemia, Myeloid, Acute · United States | 2 | Terminated | AbbVie | Apr 2017 | 36 |
| NCT02329847Hematologic Neoplasms · United States, Australia, Israel and more | 2 | Completed | Johnson & Johnson | Feb 9, 2022 | 144 |
| NCT02271438Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2015 | 28 |
| NCT02264574Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | AbbVie | Mar 26, 2018 | 229 |
| NCT02195869Graft vs Host Disease · United States | 2 | Completed | AbbVie | Sep 15, 2017 | 45 |
| NCT02169180Lymphoma, Mantle-Cell · Japan | 2 | Completed | Johnson & Johnson | Nov 2016 | 16 |
| NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more | 3 | Completed | AbbVie | Nov 7, 2019 | 181 |
| NCT02142049Lymphoma · United States | 2 | Completed | AbbVie | Aug 2017 | 35 |
| NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more | 2 | Completed | AbbVie | Dec 17, 2020 | 138 |
| NCT01980628Lymphoma, B-Cell, Marginal Zone · United States, Belgium, France and more | 2 | Completed | AbbVie | Jul 2016 | 63 |
| NCT01974440Lymphoma · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | May 30, 2022 | 403 |
| NCT01973387Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, Malaysia and more | 3 | Completed | Johnson & Johnson | Dec 1, 2015 | 160 |
| NCT01980654Lymphoma, Follicular · United States | 2 | Completed | AbbVie | Nov 2017 | 80 |
| NCT01962792Multiple Myeloma · United States, Canada | 2 | Completed | AbbVie | Mar 2019 | 84 |
| NCT01969266Healthy Volunteer · United States | 1 | Completed | Johnson & Johnson | Nov 2013 | 8 |
| NCT01866033Healthy Volunteer · Belgium | 1 | Completed | Johnson & Johnson | Aug 2013 | 8 |
| NCT01855750Lymphoma · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Feb 26, 2018 | 838 |
| NCT01820936Healthy Volunteers · United States | 1 | Completed | Johnson & Johnson | Jun 2013 | 52 |
| NCT01804686Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Dec 31, 2026 | 539 |
| NCT01779791Lymphoma · United States, Australia, Belgium and more | 2 | Completed | Johnson & Johnson | May 18, 2016 | 110 |
| NCT01776840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Jun 30, 2021 | 523 |
| NCT01767948Hepatic Impairment · United States | 1 | Completed | Johnson & Johnson | Nov 2013 | 30 |
| NCT01763021Healthy Participants · United States | 1 | Completed | Johnson & Johnson | Jan 2013 | 18 |
| NCT01744691Chronic Lymphocytic Leukemia With 17p Deletion · United States, Australia, Belgium and more | 2 | Completed | AbbVie | Jun 2014 | 145 |
| NCT01724346Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Aug 18, 2023 | 269 |
| NCT01722487Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | AbbVie | May 2015 | 269 |
| NCT01704963Neoplasms · Japan | 1 | Completed | Johnson & Johnson | Nov 20, 2015 | 15 |
How it is read
Names in the registry
- “Ibrutinib”, 49 entries
- “PCI-32765”, 10 entries
- “ibrutinib”, 6 entries
- “PCI-32765 (Ibrutinib)”, 2 entries
- “SNX-5422 plus ibrutinib”, 2 entries
Codes read as this program: PCI32765.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 23 studies
- Lymphoma, Mantle-Cell, 8 studies
- Waldenstrom Macroglobulinemia, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Multiple Myeloma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.